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Abstract
Background:  Peroxisome proliferator-activated receptors (PPARs) are a class of nuclear
transcription factors that are activated by fatty acids and their derivatives. One of these, PPARγ,
regulates responsiveness to insulin in adipose cells, and PPARγ-activating drugs such as pioglitazone
are used in the treatment of type 2 diabetes. PPARγ acts in myeloid-lineage cells, including T-cells
and macrophages, to suppress their activation and their elaboration of inflammatory molecules.
PPARγ activation also suppresses the activated phenotype in microglia, suggesting that PPARγ-
activating drugs may be of benefit in chronic neuroinflammatory diseases. Some, but not all,
nonsteroidal anti-inflammatory agents (indomethacin and ibuprofen in particular) also have
activating effects on PPARγ.
Discussion and conclusions: These observations suggest on the one hand a role for PPARγ-
activating drugs in the treatment of chronic neuroinflammatory diseases-as shown for a patient with
secondary progressive multiple sclerosis by Pershadsingh et al. in this issue of the Journal of
Neuroinflammation-and suggest on the other hand a possible explanation for confusing and
contradictory results in trials of nonsteroidal anti-inflammatory agents in Alzheimer's disease.
Introduction
There are still times in modern medicine when a single
patient can enlighten our understanding of a disease or
disease process, and can serve as an impetus for further
discovery. In this issue of Journal of Neuroinflammation,
Harrihar Pershadsingh and his colleagues [1] describe sta-
bilization and, indeed, clinical improvement in a patient
with progressive secondary multiple sclerosis who was
treated with pioglitazone over a three-year period. These
observations suggest that larger, controlled trials of such
treatment may be warranted.
The possible connection between pioglitazone and multi-
ple sclerosis is a fascinating story in itself, and one that not
only provides interesting parallels between chronic CNS
inflammatory diseases and chronic peripheral diseases,
but also illuminates an area of current interest for diseases
such as Alzheimer's disease as well.
Discussion
Pioglitazone is currently used in the treatment of type 2
diabetes. The mechanism of action involves activation of
a nuclear transcription factor known as the peroxisome
proliferator-activated receptor gamma, or PPARγ, that
controls lipid metabolism in adipocytes, and sensitizes
these cells to insulin. PPARγ agonists also suppress T-cell
activation suggesting that they may be useful in treating
inflammatory diseases. Moreover, activation of PPARγ in
microglia (as well as in macrophages) results in decreased
activation of these cells, with decreased expression of pro-
inflammatory cytokines and related molecules. This sug-
gests that PPARγ agonists might be useful in a number of
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central nervous system diseases with inflammatory com-
ponents.
Peroxisomes, or microbodies as they were originally
known, were discovered by early electron microscopists in
the 1950s [2]. Christian de Duve, in Brussels, Belgium,
subsequently isolated these structures, demonstrated
hydrogen peroxide generation, and renamed them perox-
isomes [3]. The discovery of PPARs grew out of the War on
Cancer in the 1970s. A class of drugs was identified that
promoted cancer-like growths in animals, but that did not
cause DNA damage [4]. What these drugs did do was to
stimulate proliferation of peroxisomes in target cells. At
the time, this suggested a specific genetic trigger for tum-
origenesis, and there ensued two decades of attempts to
identify the receptor for these peroxisome proliferation-
activating drugs.
By the 1990s, when PPARs were identified and shown to
be transcription factors [5], interest had waned in cancer
circles. PPARs are a class of transcription factors that are
activated by fatty acids and their derivatives. They were
found to control a number of genes, most of which have
little or nothing to do with peroxisomes. PPARγ is impor-
tant both in fat cell metabolism and in modulating cellu-
lar responsiveness to insulin - hence the connection with
diabetes [6]. PPARγ-activating drugs were subsequently
found to regulate T-cell responsiveness [7,8] and to sup-
press macrophage and microglia activation [9-11]. Both of
these actions are relevant to multiple sclerosis, and may
have implications for other chronic neurodegenerative
diseases as well. In addition to pioglitazone, some (but
not all) nonsteroidal anti-inflammatory drugs (in particu-
lar indomethacin and ibuprofen) have activating effects
on PPARγ in addition to their effects on cyclooxygenase
[12]. NSAID use has been linked with decreased risk of
Alzheimer's disease in epidemiological studies [13-15],
but prospective trials of NSAIDs in Alzheimer patients
have yielded contradictory and inconclusive results [16-
18]. The NSAID-PPARγ connection might explain some of
these contradictions, as the only one of these clinical trials
that reported a benefit was also the only one that used a
PPARγ-activating drug [16]. There are currently two clini-
cal trials in progress testing the efficacy of PPARγ agonists
in AD patients.
Conclusions
Pioglitazone and related drugs activate PPARγ, and activa-
tion of PPARγ suppresses T-cell, macrophage, and micro-
glial immune responses. If suppression of these immune
responses is of potential benefit for inflammatory diseases
of the brain, then pioglitazone should provide therapeutic
benefit in multiple sclerosis. Multiple sclerosis, of course,
is notoriously variable in its course, but the secondary
progressive variant is an exception to this. Pershadsingh et
al. show clinical stabilization in such a patient, treated for
three years with the PPARγ-activating drug pioglitazone.
This single clinical case thus provides support for a link
between PPARγ activation and suppression of neuroin-
flammation, and suggests avenues of research for the fur-
ther treatment of multiple sclerosis as well as other
chronic neuroinflammatory diseases.
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